title: Modulation of the effects of lung immune response on bone marrow by oral antigen exposure.
abstract: Allergic airway inflammation is attenuated by oral tolerization (oral exposure to allergen, followed by conventional sensitization and challenge with homologous antigen), which decreases airway allergen challenge-induced eosinophilic infiltration of the lungs and bone marrow eosinophilia. We examined its effects on bone marrow eosinophil and neutrophil production. Mice of wild type (BP-2, BALB/c, and C57BL/6) and mutant strains (lacking iNOS or CD95L) were given ovalbumin (OVA) or water (vehicle) orally and subsequently sensitized and challenged with OVA (OVA/OVA/OVA and H2O/OVA/OVA groups, resp.). Anti-OVA IgG and IgE, bone marrow eosinophil and neutrophil numbers, and eosinophil and neutrophil production ex vivo were evaluated. T lymphocytes from OVA/OVA/OVA or control H2O/OVA/OVA donors were transferred into naïve syngeneic recipients, which were subsequently sensitized/challenged with OVA. Alternatively, T lymphocytes were cocultured with bone marrow eosinophil precursors from histocompatible sensitized/challenged mice. OVA/OVA/OVA mice of the BP-2 and BALB/c strains showed, relative to H2O/OVA/OVA controls, significantly decreased bone marrow eosinophil counts and ex vivo eosinopoiesis/neutropoiesis. Full effectiveness in vivo required sequential oral/subcutaneous/intranasal exposures to the same allergen. Transfer of splenic T lymphocytes from OVA/OVA/OVA donors to naive recipients prevented bone marrow eosinophilia and eosinopoiesis in response to recipient sensitization/challenge and supressed eosinopoiesis upon coculture with syngeneic bone marrow precursors from sensitized/challenged donors.
authors.affiliation: Department of Immunology, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Brazil.
authors.forename: P
authors.initials: P
authors.lastname: Xavier-Elsas
authors.forename: C L C A
authors.initials: CL
authors.lastname: Silva
authors.forename: L
authors.initials: L
authors.lastname: Pinto
authors.forename: T
authors.initials: T
authors.lastname: Queto
authors.forename: B M
authors.initials: BM
authors.lastname: Vieira
authors.forename: M G
authors.initials: MG
authors.lastname: Aranha
authors.forename: B
authors.initials: B
authors.lastname: De Luca
authors.forename: D
authors.initials: D
authors.lastname: Masid-de-Brito
authors.forename: R A
authors.initials: RA
authors.lastname: Luz
authors.forename: R S
authors.initials: RS
authors.lastname: Lopes
authors.forename: R
authors.initials: R
authors.lastname: Ferreira
authors.forename: M I
authors.initials: MI
authors.lastname: Gaspar-Elsas
mesh_terms: D000284:Administration, Oral; D000485:Allergens / Q000008:administration & dosage / Q000276:immunology; D000818:Animals; D001854:Bone Marrow Cells / Q000276:immunology*; D004804:Eosinophils / Q000473:pathology; D006410:Hematopoiesis / Q000276:immunology; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology* / Q000473:pathology; D007113:Immunity, Innate; D007249:Inflammation / Q000276:immunology / Q000473:pathology; D008168:Lung / Q000276:immunology* / Q000473:pathology; D051379:Mice; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000485:Allergens; D010047:Ovalbumin